Put a price on breakthroughs

Neolabs are being asked to deliver two rare outcomes at once: a genuine research breakthrough and a venture-scale company, which multiplies already tiny odds and forces teams to split focus between long-shot science and go-to-market execution. Large frontier labs prefer to keep scaling proven approaches - more data, bigger runs, more compute - while researchers want to pursue paradigm-shifting ideas that require expensive, high-risk experiments. The proposed solution borrows from pharma: pre-registered acquisitions or “pull funding,” where a frontier lab publicly or privately commits to buy a team or its asset at a set price if it hits a pre-specified technical target. This breaks Arrow’s information paradox by making the payoff clear up front and lets researchers spend money chasing a single scientific question without shouldering product risk.

Two implementation paths are described: open offers that anyone can attempt (e.g., match an eval with 1/10th the compute for a stated price) and private option deals where a lab secures first-refusal for a set price with fallback fees. Concrete examples and numbers (a $2B offer for a 10x compute win, SpaceX/Cursor-style options) show how prices can reflect avoided future training costs. Benefits: frontier labs get vetted breakthroughs without funding every shot, neolabs can focus on research and remain aligned, and investors gain an acquisition floor to value startups. A key caveat is that AI methods aren’t easily patentable, so acquisitions must capture teams or hard-to-copy moats like unique data or approvals.